Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease
Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, Tsoutsou A, Boufidou F, Kapaki E, Vassilopoulos D. Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease.
Acta Neurol Scand 2007: 116: 374–379.
© 2007 The Authors Journal compilation © 2007 Blackwell Munksgaard.
Interleukin-15 promotes T-cell proliferation, induction of cytolytic effector cells including natural killer (NK) and cytotoxic cells and stimulates B-cell to proliferate and secrete immunoglobulins. RANTES is a C-C beta chemokine with strong chemoattractant activity for T lymphocytes and monocytes. Objectives –
The objective of our study was to find out whether IL-15 and RANTES are involved in the possible inflammatory reactions of PD. Patients and methods –
We measured by immunoassay serum IL-15 and RANTES levels in 41 patients with PD in comparison with serum levels in 19 healthy subjects age and sex-matched. IL-15 and RANTES levels were correlated with sex, age, disease duration. H-Y stage and the UPDRS III score in all the studied groups and were also correlated with treatment status in PD patients. Results –
The PD group presented with significantly increased RANTES levels as compared to the control group (P = 0.0009). No difference was observed as regards IL-15 levels. A strong and significant correlation between RANTES levels and UPDRS III score was observed in PD patients (Rs = 0.42, P = 0.007). Untreated patients had significantly higher RANTES levels as compared to the controls. Conclusions –
Our findings may suggest a recruitment of activated monocytes, macrophages and T lymphocytes to sites of inflammation in the central nervous system of PD patients.
- In this:
- By this:
- In this Subject:
Neurology & Psychiatry
- By this author:
Paraskevas, G. P.
Open access content
Free trial content